CN1347714A - Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method - Google Patents
Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method Download PDFInfo
- Publication number
- CN1347714A CN1347714A CN 01108448 CN01108448A CN1347714A CN 1347714 A CN1347714 A CN 1347714A CN 01108448 CN01108448 CN 01108448 CN 01108448 A CN01108448 A CN 01108448A CN 1347714 A CN1347714 A CN 1347714A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- ligustri lucidi
- rhizoma rhei
- fructus ligustri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese herbal medicine composition six kinds of Chinese medicinal materials and is prepared through mixing, extraction and concentration. It is prepared into capsule, emdicine powder, tablet or pills and used to treat diabetes and nephrosis in early stage and with the symptoms of Qi and Yin deficiency, impairment of liver and kidney and blood clots owing to its obvious effects of benefiting vital energy, nourishing Yin, invigorating liver and kidney, and promoting blood circulation to disperse blood clots.
Description
The present invention relates to Chinese medicine composition and preparation method thereof, be specially adapted to treat the Chinese medicine composition and the preparation method of diabetic nephropathy.
Diabetes are common frdquently encountered diseases of serious harm human health, are the third-largest diseases that is only second to cancer and cardiovascular disease.Diabetic nephropathy is one of diabetes most common complication, also is the lethal main causes of diabetes.It is reported, 30% of U.S.'s dialysis patient is a diabetic nephropathy patient, cumulative life-incidence is 40%～50% (Andersem AK, Christiansen JS, et al., Diabetic nephropathy in Type 1diabetes:An episemiological study, Diabtelogia 1983; 25:496).At home, the urine protein positive rate of diabetic is 54.2%～55.2% (Beijing, Tianjin diabetes cooperative groups, diabetic vascular complications research, CHINESE JOURNAL OF INTERNAL MEDICINE, 1981; 20:518), the diabetic nephropathy sickness rate be 16.8%～23.48% (Han Xiaoliang, Chi Zhisheng etc. are to the research of non-insulin-dependent diabetes mellitus nephropathy, Chinese Journal of Nephrology, 1989; (5): 134 and Liu Wenqin, open also sincere etc., diabetic nephropathy 58 routine clinical analysiss, Chinese Journal of Nephrology, 1986; (2): 304).In a single day nephropathy takes place and becomes in diabetic, the persistence urine protein occurs, and then the state of an illness is irreversible, is to carry out sexual development until renal failure.The diabetic nephropathy mortality rate is 17 times of non-diabetic kidney patient.Both at home and abroad the control of diabetic nephropathy is run into thorny problem: 1. a few days ago sulfaurea drugs is as gliquidone, many with infringement liver, kidney and hemocytees; With the sulphonamides cross allergy, the later stage produces secondary failure (prescription of Chinese patent publication number CN 1113146A Remedies for diabetes).2. angiotensin converting enzyme inhibitor (ACEI) class medicine, coughing is its common adverse reactions, incidence rate 43% (An Maozhu, grandson waits quietly, the untoward reaction of angiotensin-convertion enzyme inhibitor and control, Chinese Journal of New Drugs, 1999; (6): 403).3. used on the market pure Chinese medicine is less, though certain curative effect is arranged, fails to suit the remedy to the case by theory of Chinese medical science and symptom primary and secondary, and is therefore not strong to the diabetic nephropathy specific aim.
The present invention provides a kind of Chinese medicine composition at early diabetic nephropathy kidney qi Yin bivacuity, deficiency of the liver and kindey, the folder blood stasis symptom of holding concurrently a kind of diabetic nephropathy therapeutic agent evident in efficacy and preparation method thereof just in order to overcome above-mentioned weak point of the prior art.
By a large amount of diabeticss are carried out differential diagnosis in tcm, confirm that type of deficiency of both QI and YIN is the basic pattern of syndrome of diabetes, the deficiency of YIN is the intrinsic factor that cause onset diabetes, blood stasis is the pathologic basis of diabetic microvascular complication.Diabetic nephropathy is development on the basis of diabetes, and the normal touching difficulty of the state of an illness heals, " disease of the five internal organs must reach kidney thoroughly ", and " The liver and the kidney have a common source ", and cause deficiency of the liver and kindey; " pathogen usually intruding into collateral in protracted disease ", the resistance of the channels stasis of blood causes blood stasis, shows as the time of simulataneous insufficiency and excessive.So deficiency of both QI and YIN, deficiency of the liver and kindey, the folder blood stasis of holding concurrently are diabetic nephropathy pathogenesis place.Suffering from a deficiency of the kidney can not astringency inducing, and essence of water and grain is made a bet, and it is sticky as fat to urinate, and sugar and albumin excretion rate rising are arranged in the Clinical Laboratory urine.Therefore, supplementing QI and nourishing YIN, nourishing the liver and kidney, blood circulation promoting and blood stasis dispelling can be checked erroneous ideas at the outset stopping diarrhea by diaphoresis for treatment early diabetic nephropathy fundamentum.Chinese medicine composition of the present invention is as follows, and wherein composition is by weight percentage:
The Radix Astragali 20～65% Radix Pseudostellariaes 5～30% Fructus Ligustri Lucidi 5～15%
Fructus Lycii 10～30% Hirudos 10～14% Radix Et Rhizoma Rhei 5～30%
The Radix Astragali in the above-mentioned Chinese medicine composition is the dry root of leguminous plant Radix Astagali Astragalus membranacecs (Fisch.) Bge.var.mongholicus (Bge.) Hsiao or Radix Astragali Astragalus mem-branacecs (Fisch.) Bge..Its invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.It is weak to be used for the deficiency of vital energy.Anorexia and loose stool, sinking of QI of middle-JIAO, the exterior deficiency spontaneous perspiration, deficiency of vital energy edema, blood deficiency and yellow complexion, interior-heat is quenched one's thirst; Chronic nephritis proteinuria, diabetes etc.
Radix Pseudostellariae is the dried root of pinkwort Radix Ginseng Pseudostellaria heterophylla (Miq.) Pax et Paxer Hoffm..It has replenishing QI to invigorate the spleen, promoting the production of body fluid for nourishing the lung.It is tired to be used for insufficiency of the spleen body, and inappetence is weak after being ill, deficiency of both vital energy and Yin, and spontaneous perspiration is thirsty, dryness of the lung dry cough.
Fructus Ligustri Lucidi is the dry mature fruit of Oleaceae plant Fructus Ligustri Lucidi Ligustum lucidum Ait..Its nourishing the liver and kidney, black hair makes eye bright.Be used for vertigo and tinnitus, soreness of the waist and knees, early whitening of beard and hair, poor vision.
Fructus Lycii is the dry mature fruit of plant of Solanaceae lycium barbarum Lycium barbarum L..Its nourishing the liver and kidney, replenishing vital essence to improve eyesight.Be used for the asthenia damage of essence, soreness of waist and knee joint, vertigo and tinnitus, interior-heat are quenched one's thirst, blood deficiency and yellow complexion, blurred vision is not clear.
Hirudo is the dry body of Hirudinidae animal whitmania Whitmania pigra Whitman, Hirudo Hirudo nipponicaWhitman or Folium Salicis Babylonicae Hirudo Whitmania acranulata Whitman.Its removing blood stasis, removing blood stasis stimulates the menstrual flow.Yong the mass in the abdomen mass in the abdomen, blood stasis amenorrhea, injury from falling down.
Radix Et Rhizoma Rhei is the dry root and rhizome of polygonum rheum palmatum Rheum palmatum L., the historical relics Radix Et Rhizoma Rhei Rheumtanguticum Maxim.ex Baif. of Tang or Rheum officinale Rheum officinale Baill..The tool purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation.Be used for the excess-heat constipation, stagnant stomachache, jaundice due to damp-heat, heat in blood is told nosebleed etc.
The Radix Astragali and Radix Pseudostellariae mutually 5 in the above-mentioned Chinese medicine composition, and the merit that reaches supplementing QI and nourishing YIN is monarch drug altogether.The Fructus Ligustri Lucidi merit is arrogated to oneself nourishing the liver and kidney, reinforcing YIN-essence, strong waist knee joint; Fructus Lycii nourishing kidney, lung moistening, make eye bright, with Fructus Ligustri Lucidi be ministerial drug altogether.The Radix Et Rhizoma Rhei eliminating heat pathogen by purging the bowels, blood circulation promoting and blood stasis dispelling gathers by stagnant blood, blood stasis, removing blood stasis abdominal mass, relieving dyspepsia in the accent, peace and the five internal organs; The Hirudo removing blood stasis collateral dredging of invigorating blood circulation, promoting tissue regeneration by removing blood stasis, with Radix Et Rhizoma Rhei be adjuvant.Its compositions giving consideration to both the incidental and fundamental, the merit of playing supplementing QI and nourishing YIN, nourishing the liver and kidney, blood circulation promoting and blood stasis dispelling altogether.
The present invention is as follows according to the preparation method of above-mentioned composition, and carry out the process of preparing Chinese medicine of Chinese crude drug earlier: 1. the Radix Astragali is removed impurity, and size is separately cleaned, and runs through, and is cut into 2～4mm sheet, 60-80 ℃ of dry for standby; 2. Radix Pseudostellariae is removed impurity, and wash quickly is clean, is cut into 2～4mm sheet, 60-80 ℃ of dry for standby; 3. Fructus Ligustri Lucidi is removed impurity and stalk leaf, clean, and 60-80 ℃ of drying, the time spent smashs to pieces; 4. Fructus Lycii is removed impurity, chooses carpopodium, and clean and tidy back is standby; 5. Hirudo is cleaned cutting, 60-70 ℃ of dry for standby; 6. Radix Et Rhizoma Rhei is removed impurity, cleans, and runs through, and cuts straight sheet, and thickness is 2～4mm, 60-80 ℃ of oven dry, and sieve goes chip standby.
Radix Et Rhizoma Rhei after the said method process of preparing Chinese medicine is pulverized, crossed 100 mesh sieves, get fine powder and carry out radiation sterilization, 2KGY/ hour, exposure time was standby after 3 hours; The Fructus Ligustri Lucidi that the said method of learning from else's experience was concocted adds 75% ethanol of 6 times of amounts, and reflux, extract, 2-4 time each 1 hour, reclaims ethanol with alcohol extract; The medicinal residues of Fructus Ligustri Lucidi and the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, the Hirudo of concocting through said method add the water of 6 times of amounts of water, decoct 2-4 time, each 2 hours, filter, merge the water extract, remove to abandon medicinal residues, the concentrated solution that fried liquid and Fructus Ligustri Lucidi are reclaimed behind the ethanol merges, under-0.015-0.030MPa, concentrating under reduced pressure, temperature is 80 ℃, when being concentrated into the extractum relative density and being 1.05-1.15, is dried cream powder 70 ℃ of following spray dryinges, again with the sterilization after the Radix Et Rhizoma Rhei mixing cross 100 mesh sieves, pack is sealed, and every bag of 2g/ is the powder finished product.
Be prepared also referring to the flow sheet 1-4 of Figure of description by the percentage by weight of the prescription of described Chinese medicine composition and can obtain capsule, pill, tablet.
Below be the drawing explanation of Figure of description of the present invention:
Fig. 1 is preparation technology's flow chart of powder of the present invention.
Fig. 2 is preparation technology's flow chart of capsule of the present invention.
Fig. 3 is preparation technology's flow chart of pill of the present invention.
Fig. 4 is preparation technology's flow chart of tablet of the present invention.
The present invention has reduction Microproteinuria (microdose urine protein, glucose in urine egg through the zoopery proof White etc.), the protection renal function; And the effect that reduces blood sugar, blood fat arranged; Regulate RAS and The balance of prostacyclin system; Significantly improve blood flow, and then reach protection and improve renal function.
Table 1 microdose urine protein (Alb, μ g/ml) dynamically observe (the group N dosage of X ± S) (/kg/d) 8 week of 4 weeks 12 all normal group 5-12.36 ± 2.33 12.00 ± 2.19 11.77 ± 1.31 model group 7-31.51 ± 5.55△△△ 34.21±4.24
△△△ 38.31±3.82
△△△Captopril 8 4.17mg 20.65 ± 6.29*** 28.10±3.14
**34.26 ± 12.46 the present invention 8 5mg 25.78 ± 3.87* 29.66±3.03
*36.23 little 8 1.0g 27.51 of ± 5.47 Chinese medicines ± 3.71 28.66 ± 5.01* 29.18±5.26
**7 2.0g 26.34 ± 3.91 27.54 ± 5.72 in the Chinese medicine* 28.78±5.35
**Big 8 3.0g 24.34 ± 2.99 of Chinese medicine*** 26.49±5.61
* 24.43±5.55
***Compare with model group: * p＜0.05, * * p＜0.01, * * * p＜0.001. Compare with normal group: △ △ △ p＜0.001. Can significantly be reduced the microdose urine protein of diabetes rat by table 1 explanation the present invention.
Table 2 glucose in urine albumen (THP, μ g/24h) dynamic change relatively (the group N dosage of X ± S) (/kg/d) 8 week of 4 weeks 12 all normal group 5-24.56 ± 10.99 24.80 ± 9.97 25.03 ± 5.20 model group 7-791.14 ± 136.03△△△ 885.79±262.47
△△△ 952.55±12.67
△△△Captopril 7 4.17mg 496.40 ± 141.70** 549.59±188.83
* 616.55±302.77
*The present invention 8 5mg 610.83 ± 112.51*754.06 little 8 1.0g 701.04 ± 138.61 568.08 ± 191.16 of ± 197.05 805.62 ± 199.35 Chinese medicines* 545.00±152.03
**7 2.0g 630.14 ± 218.59 557.21 ± 193.14 in the Chinese medicine* 530.05±160.29
**Big 8 3.0g 458.13 ± 187.40 of Chinese medicine** 493.12±189.29
** 425.12±165.15
**Compare with model group: * p＜0.05, * * p＜0.01, * * * p＜0.001. Compare with normal group: △ △ △ p＜0.001. Can significantly be reduced the glucose in urine albumen of diabetes rat by table 2 explanation the present invention.
Table 3 urine β 2-MG (ng/ml) dynamic change relatively (the group N dosage of X ± S) (/kg/d) 8 week of 4 weeks 12 all normal group 5-0.19 ± 0.13 0.11 ± 0.05 0.12 ± 0.08 model group 7-1.37 ± 0.42△△ 1.81±0.24
△△△ 2.20±0.43
△△△Captopril 8 4.17mg 1.13 ± 0.27 1.60 ± 0.29*1.83 ± 0.29 the present invention 8 5mg 1.21 ± 0.34 1.31 ± 0.40* 1.25±0.33
**Little 8 1.0g 1.05 of Chinese medicine ± 0.30 0.81 ± 0.28** 1.21±0.36
**8 2.0g 0.92 ± 0.32 in the Chinese medicine* 0.80±0.32
** 1.17±0.43
**Big 8 3.0g 0.98 ± 0.23 of Chinese medicine* 0.92±0.23
** 1.00±0.22
**Compare with model group: * p＜0.05, * * p＜0.01. Compare with normal group: △ △ p＜0.01, △ △ △ p＜0.001. Can significantly be reduced the urine β of diabetes rat by table 3 explanation the present invention2Microglobulin.
Table 4 fasting blood-glucose and glycosylated hemoglobin variation comparison (X ± S)
Blood sugar (mmol/L) glycosylated hemoglobin (%) group
4 all 8 all 12 all 4 all 12 all normal group 5.27 ± 0.49 5.46 ± 0.53 4.98 ± 1.62 5.27 ± 0.50 5.46 ± 0.6 model group 28.17 ± 2.27△△△ 23.36±1.95
△△△ 29.52±2.05
△△△ 18.96±1.38
△△△ 16.14±1.3
△△△Captopril 25.79 ± 3.82 19.39 ± 3.13* 24.76±3.60
** 17.54±2.28 13.69±1.87
*The present invention 16.21 ± 2.01*** 14.19±3.41
*** 17.78±6.36
*** 11.80±1.17
*** 10.64±2.07
***Chinese medicine is little by 24.67 ± and 4.11 13.75 ± 1.82*** 22.53±2.33
*** 16.68±2.42
* 10.6±1.26
***In the Chinese medicine 23.83 ± 4.32* 13.22±1.69
*** 14.60±1.48
*** 16.34±2.58
* 10.19±1.00
***Chinese medicine is big by 20.33 ± 2.58*** 11.96±1.51
*** 12.31±5.93
*** 14.14±1.74
*** 9.20±0.9
***Compare with model group: * p＜0.05, * * p＜0.01, * * * p＜0.001. Compare with normal group: △ △ △ p＜0.001. Can significantly be reduced blood sugar and the glycosylated hemoglobin of diabetes rat by table 4 explanation the present invention.
Table 5 the present invention treats after 8 weeks the impacts of rat glucose tolerance (X ± S)
Blood glucose value (mmol/L) group to different time after the glucose gavage
0min 30min 60min 90min 120min AUC (mmol/L/h) normal group 4.79 ± 0.32 9.04 ± 0.64 13.91 ± 0.74 10.70 ± 1.63 7.52 ± 0.46 166.54 ± 16.47 model group 18.47 ± 1.68△△△ 22.89±1.88
△△△ 23.51±1.96
△△△ 21.43±2.63
△△△ 16.56±2.63
△△△ 972.07±188.14
△△△Captopril 16.66 ± 1.60 19.92 ± 1.39** 19.50±1.13
*** 17.32±1.44
** 14.70±1.36 737.22±114.47
**The present invention 8.11 ± 1.51*** 12.03±1.52
*** 16.02±1.57
*** 12.28±1.27
*** 11.03±1.10
*** 420.00±242.35
***Chinese medicine is little by 11.14 ± 1.02*** 16.17±1.16
*** 15.64±0.98
*** 14.11±1.14
*** 12.18±1.04
*** 480.33±71.66
***In the Chinese medicine 10.94 ± 1.15*** 15.66±1.27
*** 15.20±1.25
*** 13.95±1.13
*** 11.82±1.20
*** 432.38±77.92
***Chinese medicine is big by 9.80 ± 0.95*** 13.52±0.89
*** 13.81±0.74
*** 12.97±0.96
*** 11.27±0.98
*** 343.87±46.35
***Compare with model group: * p＜0.05, * * p＜0.01, * * * p＜0.001. Compare with normal group: △ △ △ p＜0.001. The present invention can significantly improve the IGT of diabetes rat by table 5 explanation, thereby can effectively reduce height Blood sugar.
Table 6 the present invention (8 week after) is to the impact of plasma insulin (X ± S)
To different time plasma insulin (μ IU/ml) group after the glucose gavage
0min 30min 60min 120min normal group 28.95 ± 1.17 40.50 ± 1.50 48.10 ± 0.91 37.63 ± 0.57 model group 18.38 ± 0.56△△△ 26.39±1.21
△△△ 24.01±1.15
△△△ 20.40±0.93
△△△Captopril 18.02 ± 0.62 25.08 ± 1.12 24.07 ± 0.96 21.87 ± 0.95 the present invention 24.11 ± 1.25*** 40.62±1.46
*** 31.64±1.37
*** 24.56±0.63
***Chinese medicine is little by 19.10 ± 0.55* 29.66±2.08
** 28.44±1.87
***21.08 in ± 1.59 Chinese medicines 18.32 ± 2.07 30.25 ± 2.50** 28.45±2.18
***21.44 ± 1.51 Chinese medicines are big by 26.65 ± 1.04*** 40.61±1.53
*** 29.93±1.73
*** 23.37±1.93
**Compare with model group: * p＜0.05, * * p＜0.01, * * * p＜0.001. Compare with normal group: △ △ △ p＜0.001. Illustrate that by table 6 the present invention can promote the insulin secretion of diabetes rat, improve plasma insulin level, Thereby can effectively reduce blood sugar.
The comparison of table 7 treatment metanephros changes of function (X ± S)
Group Scr (μ moL) BUN (mmol/L) Ccr (ml/min) normal group
4 weekends 67.18 ± 4.42 5.85 ± 0.24 0.98 ± 0.16
12 weekends 60.11 ± 7.07 5.96 ± 0.51 0.92 ± 0.16 model group
4 weekends 61.88 ± 8.84 9.79 ± 1.59
△ △ △1.81 ± 0.13
△ △ △
12 weekends 91.94 ± 16.79
△ △14.64 ± 2.16
△ △ △1.37 ± 0.29
△ △Captopril
4 weekends 60.12 ± 0.97 9.77 ± 0.97 1.36 ± 0.16
* *
12 weekends 73.37 ± 20.33 13.08 ± 1.76 1.08 ± 0.15
*The present invention
4 weekends 58.34 ± 7.86 9.60 ± 1.04 1.43 ± 0.18
* *
12 weekends 83.09 ± 19.45 12.19 ± 3.09 1.03 ± 0.20
*Chinese medicine is little
4 weekends 65.41 ± 6.18 9.68 ± 0.96 1.13 ± 0.17
*
12 weekends 64.97 ± 13.82
*12.04 ± 2.96 1.09 ± 0.14
*In the Chinese medicine
4 weekends 62.98 ± 7.06 9.46 ± 1.08 1.26 ± 0.13
* *
12 weekends 61.88 ± 16.79
*12.43 ± 1.26
*1.08 ± 0.20
*Chinese medicine is big
4 weekends 62.94 ± 5.65 8.47 ± 1.26 1.30 ± 0.28
* *
12 weekends 68.95 ± 9.72
*11.53 ± 3.24
*0.93 ± 0.18
*Compare with model group: * p＜0.05, * * p＜0.01, * * * p＜0.001.Compare with normal group: △ △ p＜0.01, △ △ △ p＜0.001.Can reduce Scr, the BUN of diabetes rat by table 7 explanation the present invention, reduce Ccr and the height that alleviates glomerule filters, HT, renal function protecting.
The back Blood Lipid comparison of table 8 treatment (X ± S)
Group TG (mmol/L) TC (mol/L) HDL-C (mmol/L) LDL-C (mmol/L) normal group
4 weekends 1.04 ± 0.10 1.34 ± 0.16 0.84 ± 0.09 0.78 ± 0.28
12 weekends 1.01 ± 0.09 1.32 ± 0.19 1.38 ± 0.73 0.66 ± 0.75 model group
4 weekends 3.96 ± 0.78
△ △ △2.22 ± 0.58
△ △1.34 ± 0.68 1.19 ± 0.67
12 weekends 4.41 ± 0.96
△ △ △2.93 ± 0.82
△ △1.32 ± 0.51 1.10 ± 0.21 captopril
4 weekends 2.22 ± 0.63
* *2.89 ± 0.62 0.94 ± 0.21 1.30 ± 0.27
12 weekends 3.29 ± 1.15 2.21 ± 0.19 1.67 ± 0.67 1.17 ± 0.22 the present invention
4 weekends 2.94 ± 0.87
*2.26 ± 0.44 1.19 ± 0.42 1.74 ± 0.48
12 weekends 3.22 ± 0.88
*2.67 ± 0.50 1.44 ± 0.59 0.98 ± 0.22 Chinese medicine is little
4 weekends 3.20 ± 0.58
*2.76 ± 0.35 1.02 ± 0.19 1.51 ± 0.67
12 weekends 3.17 ± 0.50
*2.08 ± 0.27
*2.27 ± 0.13
* *0.94 in ± 0.22 Chinese medicine
4 weekends 2.71 ± 0.96
*2.55 ± 0.34 1.02 ± 0.26 1.42 ± 0.74
12 weekends 3.46 ± 1.52 2.03 ± 0.21
*2.35 ± 0.42
* *0.94 ± 0.24 Chinese medicine is big
4 weekends 1.53 ± 0.27
* *2.91 ± 0.84 1.07 ± 0.08 0.92 ± 0.19
12 weekends 2.04 ± 0.64
* *1.91 ± 0.45
*1.93 ± 0.60 0.70 ± 0.11
* *Compare with model group: * p＜0.05, * * p＜0.01, * * * p＜0.001.Compare with normal group: △ p＜0.05, △ △ p＜0.01, △ △ △ p＜0.001.Can significantly improve the lipid metabolism of diabetes rat by table 8 explanation the present invention.
Table 9 is treated afterwards, and ANP, AI, AII change relatively (X ± S)
Group ANP (pg/ml) Al (ng/ml) AII (pg/ml) normal group
4 weekends 52.80 ± 9.78 1.51 ± 0.68 79.53 ± 19.24
12 weekends 51.26 ± 14.01 0.92 ± 0.44 69.78 ± 14.75 model group
4 weekends 107.06 ± 26.44
△ △ △3.31 ± 0.94
△ △ △255.70 ± 71.07
△ △ △
12 weekends 139.63 ± 34.54
△ △ △4.27 ± 0.79
△ △ △284.03 ± 71.90
△ △ △Captopril
4 weekends 69.98 ± 10.05
*3.29 ± 0.62 172.38 ± 63.46
*
12 weekends 76.89 ± 18.00
* *3.51 ± 0.71 192.45 ± 57.39
*The present invention
4 weekends 82.24 ± 14.51
*2.86 ± 0.78 207.46 ± 69.23
12 weekends 99.03 ± 31.36
*3.03 ± 1.31 238.60 ± 69.10 Chinese medicines are little
4 weekends 81.73 ± 12.76
*1.72 ± 0.34
* *192.81 ± 63.59
12 weekends 81.76 ± 17.48
*1.22 ± 0.36
* *193.30 ± 53.81
*In the Chinese medicine
4 weeks
* *End 79.20 ± 13.31
*1.69 ± 0.35
* *186.45 ± 66.45
12 weekends 79.35 ± 19.85
* *1.15 ± 0.33
* *187.79 ± 56.04
*Chinese medicine is big
4 weekends 84.45 ± 9.06
*0.73 ± 0.22
* *176.61 ± 31.98
*
12 weekends 84.48 ± 14.58
*0.73 ± 0.17
* *163.51 ± 30.86
* *Compare with model group: * p＜0.05, * * p＜0.01, * * * p＜0.001; Compare with normal group: △ △ △ p＜0.001.Can significantly reduce atrial natriuretic peptide, the angiotensin level of diabetes rat by table 9 explanation the present invention, improve high filtration of glomerule due to the diabetes, improve renal blood flow.
12 week of table 10 treatment back serum ET-1, TXB
2, 6-keto-PGF
1aChange (X ± S)
Group ET-1 (pg/ml) TXB
2(pg/ml) 6-keto-PGF1a (pg/ml)
Normal group 41.25 ± 12.97 63.93 ± 23.58 72.71 ± 8.56
Model group 130.23 ± 39.29
△ △ △169.52 ± 26.48
△ △ △40.01 ± 7.33
△ △ △
Captopril 77.81 ± 22.88
*126.44 ± 34.60
*50.88 ± 11.16
*
The present invention 90.26 ± 29.14
*97.42 ± 21.06
* *62.76 ± 14.37
*
Chinese medicine is little by 62.48 ± 19.40
* *73.93 ± 12.40
* *76.56 ± 19.59
* *
In the Chinese medicine 55.74 ± 43.35
* *72.72 ± 12.93
* *80.31 ± 23.78
* *
Chinese medicine is big by 48.68 ± 12.13
* *81.16 ± 33.38
* *70.04 ± 25.91
*Compare with model group: * p＜0.05, * * p＜0.01, * * * p＜0.001.Compare with normal group: △ p＜0.05, △ △ p＜0.01, △ △ △ p＜0.001.Can reduce Endothelin, the thromboxance B of diabetes rat by table 10 explanation the present invention
2, improve 6-ketone-prostacyclin level, regulate the dynamic equilibrium of feritin-prostacyclin system, improve renal blood flow.
Respectively organize hemorheology after table 11 treatment and change relatively (X ± S)
Whole blood viscosity
The packed cell volume erythrocyte gathers the group plasma viscosity
(%) aggregate index number
Height is cut
(cp) 200In cut
(cp) 100Low cutting
(cp) 5Normal group 5.59 ± 0.30 13.26 ± 0.77 21.92 ± 2.54 0.49 ± 0.07 3.29 ± 0.12 3.21 ± 0.45 model group 8.37 ± 0.50
△ △ △25.80 ± 0.74
△ △ △27.25 ± 1.03
△0.51 ± 0.03 5.01 ± 0.24
△ △4.30 ± 0.32
△Captopril 7.63 ± 1.12 13.98 ± 0.84
* *23.06 ± 0.73
* *0.55 ± 0.35 3.35 ± 0.66
* *3.22 ± 0.30
* *The present invention 8.99 ± 0.42
*15.59 ± 0.81
* *26.67 ± 1.39 0.51 ± 0.05 3.69 ± 0.41
* *4.07 ± 0.42
*Chinese medicine is little by 6.46 ± 0.26
* *13.02 ± 1.02
* *23.17 ± 1.59
* *0.55 ± 0.03 3.85 ± 0.33
* *3.59 ± 0.27
* *In the Chinese medicine 6.16 ± 0.70
* *12.84 ± 1.02
* *21.25 ± 1.45
* *0.53 ± 0.05 3.77 ± 0.370
* *3.66 ± 0.36
*Chinese medicine is big by 6.14 ± 0.47
* *11.67 ± 1.30
* *20.35 ± 3.55
* *0.51 ± 0.01 3.36 ± 0.27
* *3.28 ± 0.20
* *Compare with model group: * p＜0.05, * * p＜0.01, * * * p＜0.001.Compare with normal group: △ p＜0.05, △ △ p＜0.01, △ △ △ p＜0.001.Table 11 explanation the present invention can significantly improve the hemorheological property of diabetes rat.
Through animal experiment and clinical observation, the present invention has effect preferably to the control diabetic nephropathy.
The present invention also has following advantage:
1. the present invention is a compositions of selecting for use Six-element Chinese medicine to form, has no side effect.
2. the present invention is by the differential diagnosis in tcm theory, and is at the diabetic nephropathy symptomatic treatment, with strong points for this reason, evident in efficacy.
3. the present invention can be made into powder, capsule, tablet, pill, and volume is little, is convenient to take and carry.
The present invention is described in further detail below with reference to embodiment and Figure of description:
1. 1 kinds of Chinese medicine compositions for the treatment of diabetic nephropathy of embodiment are made up of the Radix Astragali, Radix Pseudostellariae, Fructus Ligustri Lucidi, Fructus Lycii, Hirudo, Radix Et Rhizoma Rhei Six-element Chinese medicine, and the percentage by weight of its composition is as follows:
The Radix Astragali 65% Radix Pseudostellariae 5% Fructus Ligustri Lucidi 5%
Fructus Lycii 10% Hirudo 10% Radix Et Rhizoma Rhei 5%
Above-mentioned Chinese medicine composition is prepared as powder, and at first carry out the process of preparing Chinese medicine of Chinese crude drug: 1. the Radix Astragali is removed impurity, and size is separately cleaned, and runs through, and is cut into 2～4mm sheet, 60-80 ℃ of dry for standby; 2. Radix Pseudostellariae is removed impurity, and wash quickly is clean, is cut into 2～4mm sheet, 60-80 ℃ of dry for standby; 3. Fructus Ligustri Lucidi is removed impurity and stalk leaf, clean, and 60-80 ℃ of drying, the time spent smashs to pieces; 4. Fructus Lycii is removed impurity, chooses carpopodium, and clean and tidy back is standby; 5. Hirudo is cleaned cutting, 60-70 ℃ of dry for standby; 6. Radix Et Rhizoma Rhei is removed impurity, cleans, and runs through, and cuts straight sheet, and thickness is 2～4mm, 60-80 ℃ of oven dry, and sieve goes chip standby;
Referring to Figure of description 1, the Radix Et Rhizoma Rhei after the said method process of preparing Chinese medicine is pulverized, cross 100 mesh sieves, get fine powder and carry out radiation sterilization, 2KGY/ hour, exposure time was standby after 3 hours; The Fructus Ligustri Lucidi that the said method of learning from else's experience was concocted adds 75% ethanol of 6 times of amounts, and reflux, extract, 2-4 time each 1 hour, reclaims ethanol with alcohol extract; The medicinal residues of Fructus Ligustri Lucidi and the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, the Hirudo of concocting through said method add the water of 6 times of amounts of water, decoct 2-4 time, each 2 hours, filter, merge the water extract, remove to abandon medicinal residues, the concentrated solution that fried liquid and Fructus Ligustri Lucidi are reclaimed behind the ethanol merges, under-0.015-0.030MPa, concentrating under reduced pressure, temperature is 80 ℃, when being concentrated into the extractum relative density and being 1.05-1.15, is dried cream powder 70 ℃ of following spray dryinges, again with the sterilization after the Radix Et Rhizoma Rhei mixing cross 100 mesh sieves, pack is sealed, and every bag of 2g/ is the powder finished product.
The method of taking is: each 1 bag, every day 3 times, use warm boiled water.
2. 1 kinds of Chinese medicine compositions for the treatment of diabetic nephropathy of embodiment are made up of the Radix Astragali, Radix Pseudostellariae, Fructus Ligustri Lucidi, Fructus Lycii, Hirudo, Radix Et Rhizoma Rhei Six-element Chinese medicine, and the percentage by weight of its composition is as follows:
The Radix Astragali 23% Radix Pseudostellariae 30% Fructus Ligustri Lucidi 15%
Fructus Lycii 10% Hirudo 14% Radix Et Rhizoma Rhei 8%
Referring to Figure of description 2, above-mentioned Chinese medicine composition is prepared as capsule, the process of preparing Chinese medicine of its Chinese crude drug is basic identical with embodiment 1 with the method for preparation, just behind the dried cream powder that obtains Fructus Ligustri Lucidi, the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, Hirudo, again with sterilization after the Radix Et Rhizoma Rhei mixing make granule, 60 ℃ of following airpillow-dry 1 hour, in incapsulating, every is equivalent to primary crude drug 1.494g, and every heavy 0.5g is the capsule finished product.
The method of taking is: each 4, every day three times, use warm boiled water.
3. 1 kinds of Chinese medicine compositions for the treatment of diabetic nephropathy of embodiment are made up of the Radix Astragali, Radix Pseudostellariae, Fructus Ligustri Lucidi, Fructus Lycii, Hirudo, Radix Et Rhizoma Rhei Six-element Chinese medicine, and the percentage by weight of its composition is as follows:
The Radix Astragali 30% Radix Pseudostellariae 10% Fructus Ligustri Lucidi 10%
Fructus Lycii 10% Hirudo 10% Radix Et Rhizoma Rhei 30%
Referring to Figure of description 3, above-mentioned Chinese medicine composition is prepared as pill, the process of preparing Chinese medicine of its Chinese crude drug is basic identical with embodiment 1 with the method for preparation, just behind the extractum that obtains Fructus Ligustri Lucidi, the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, Hirudo, again with pulverized 60 mesh sieves, the Radix Et Rhizoma Rhei mixing after the sterilization, drying is 1 hour under 60 ℃, pulverizes, and crosses 60 mesh sieves, use pure water pill, per 20 the heavy 1g of the watered pill, coating, polishing, 60 ℃ of dryings are the pill finished product.
The method of taking is: each 1 ball, every day three times, use warm boiled water.
4. 1 kinds of Chinese medicine compositions for the treatment of diabetic nephropathy of embodiment are made up of the Radix Astragali, Radix Pseudostellariae, Fructus Ligustri Lucidi, Fructus Lycii, Hirudo, Radix Et Rhizoma Rhei Six-element Chinese medicine, and the percentage by weight of its composition is as follows:
The Radix Astragali 20% Radix Pseudostellariae 20% Fructus Ligustri Lucidi 10%
Fructus Lycii 30% Hirudo 10% Radix Et Rhizoma Rhei 10%
Referring to Figure of description 4, above-mentioned Chinese medicine composition is prepared as tablet, the process of preparing Chinese medicine of its Chinese crude drug is basic identical with embodiment 1 with the method for preparation, just behind the extractum that obtains Fructus Ligustri Lucidi that relative density is 1.20-1.30, the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, Hirudo, again with pulverized 120 mesh sieves, the Radix Et Rhizoma Rhei mixing after the sterilization adds supplementary product starch (benefit ratio?) mixing, make granule, drying is 1 hour under 60 ℃, tabletting, and sheet is heavy: the 0.5g/ sheet, the bag film-coat is the tablet finished product.
The method of taking is: each 6, every day three times, use warm boiled water.
Claims (5)
1. Chinese medicine composition for the treatment of diabetic nephropathy, it is characterized in that: be made up of the Radix Astragali, Radix Pseudostellariae, Fructus Ligustri Lucidi, Fructus Lycii, Hirudo, Radix Et Rhizoma Rhei Six-element Chinese medicine, the percentage by weight of its composition is as follows:
The Radix Astragali 20～65% Radix Pseudostellariaes 5～30% Fructus Ligustri Lucidi 5～15%
Fructus Lycii 10～30% Hirudos 10～14% Radix Et Rhizoma Rhei 5～30%
Can make powder, capsule, pill or tablet.
2. one kind prepares the method that claim 1 prescription is used for the treatment of the Chinese medicine composition composition powders of diabetic nephropathy,
It is characterized in that: carry out the process of preparing Chinese medicine of Chinese crude drug earlier:
2.1 the Radix Astragali is removed impurity, size is separately cleaned, and runs through, and is cut into 2～4mm sheet, 60-80 ℃ of dry for standby;
2.2 Radix Pseudostellariae is removed impurity, wash quickly is clean, is cut into 2～4mm sheet, 60-80 ℃ of dry for standby;
2.3 Fructus Ligustri Lucidi is removed impurity and stalk leaf, cleans, and 60-80 ℃ of drying, the time spent smashs to pieces;
2.4 Fructus Lycii is removed impurity, chooses carpopodium, clean and tidy back is standby;
2.5 Hirudo is cleaned cutting, 60-70 ℃ of dry for standby;
2.6 Radix Et Rhizoma Rhei is removed impurity, cleans, and runs through, and cuts straight sheet, thickness is 2～4mm, 60-80 ℃ of oven dry, and sieve goes chip standby;
Radix Et Rhizoma Rhei after the said method process of preparing Chinese medicine is pulverized, crossed 100 mesh sieves, get fine powder and carry out radiation sterilization, 2KGY/ hour, exposure time was standby after 3 hours; The Fructus Ligustri Lucidi that the said method of learning from else's experience was concocted adds 75% ethanol of 6 times of amounts, and reflux, extract, 2-4 time each 1 hour, reclaims ethanol with alcohol extract; The medicinal residues of Fructus Ligustri Lucidi and the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, the Hirudo of concocting through said method add the water of 6 times of amounts of water, decoct 2-4 time, each 2 hours, filter, merge the water extract, remove to abandon medicinal residues, the concentrated solution that fried liquid and Fructus Ligustri Lucidi are reclaimed behind the ethanol merges, under-0.015-0.030MPa, concentrating under reduced pressure, temperature is 80 ℃, when being concentrated into the extractum relative density and being 1.05-1.15, is dried cream powder 70 ℃ of following spray dryinges, again with the sterilization after the Radix Et Rhizoma Rhei mixing cross 100 mesh sieves, pack is sealed, and every bag of 2g/ is the powder finished product.
3. one kind prepares the method that claim 1 prescription is used for the treatment of the Chinese medicinal composition capsules agent of diabetic nephropathy, it is characterized in that: the process of preparing Chinese medicine of Chinese crude drug is basic identical with claim 2 with the method for preparation, just behind the dried cream powder that obtains Fructus Ligustri Lucidi, the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, Hirudo, again with the sterilization after the Radix Et Rhizoma Rhei mixing make granule, 60 ℃ of following airpillow-dry 1 hour, in incapsulating, every was equivalent to primary crude drug 1.494g, every heavy 0.5g is the capsule finished product.
4. one kind prepares the method that claim 1 prescription is used for the treatment of the Chinese medicine composition pill of diabetic nephropathy, it is characterized in that: the process of preparing Chinese medicine of Chinese crude drug is basic identical with claim 2 with the method for preparation, just behind the extractum that obtains Fructus Ligustri Lucidi, the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, Hirudo, again with pulverized 60 mesh sieves, the Radix Et Rhizoma Rhei mixing after the sterilization, 60 ℃ dry 1 hour down, pulverize, cross 60 mesh sieves, use pure water pill, per 20 the heavy 1g of the watered pill, coating, polishing, 60 ℃ of dryings are the pill finished product.
5. one kind prepares the method that claim 1 prescription is used for the treatment of the Chinese medicine composition tablet of diabetic nephropathy, it is characterized in that: the process of preparing Chinese medicine of Chinese crude drug is basic identical with claim 2 with the method for preparation, just behind the extractum that obtains Fructus Ligustri Lucidi that relative density is 1.20-1.30, the Radix Astragali, Radix Pseudostellariae, Fructus Lycii, Hirudo, again with pulverized 120 mesh sieves, Radix Et Rhizoma Rhei mixing after the sterilization, add supplementary product starch 10%, mixing, make granule, drying is 1 hour under 60 ℃, tabletting, and sheet is heavy: the 0.5g/ sheet, the bag film-coat is the tablet finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011084480A CN1166382C (en) | 2001-05-21 | 2001-05-21 | Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011084480A CN1166382C (en) | 2001-05-21 | 2001-05-21 | Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1347714A true CN1347714A (en) | 2002-05-08 |
| CN1166382C CN1166382C (en) | 2004-09-15 |
Family
ID=4657265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011084480A Expired - Lifetime CN1166382C (en) | 2001-05-21 | 2001-05-21 | Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1166382C (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049440B (en) * | 2006-04-03 | 2010-11-10 | 北京因科瑞斯生物制品研究所 | Preparation of Chinese traditional medicine in use for diabetes, and preparation method |
| CN101940716A (en) * | 2010-09-19 | 2011-01-12 | 薛红云 | Medicament for treating diabetic nephropathy |
| CN102100858A (en) * | 2011-01-29 | 2011-06-22 | 傅晓骏 | Chinese medicinal preparation for treating early diabetic nephropathy and preparation method thereof |
| CN101890098B (en) * | 2009-05-21 | 2012-03-14 | 中国中医科学院广安门医院 | Medicament for treating type II diabetic cardiopathy and preparation method thereof |
| CN102670842A (en) * | 2012-05-11 | 2012-09-19 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating diabetic nephropathy |
| CN102784237A (en) * | 2011-05-17 | 2012-11-21 | 成都康弘制药有限公司 | Pharmaceutical composition for preventing or treating diabetic complications |
| CN102784238A (en) * | 2011-05-17 | 2012-11-21 | 成都康弘制药有限公司 | Application of pharmaceutical composition in preparation of drugs for preventing or treating neovascular diseases |
| CN103301243A (en) * | 2012-03-14 | 2013-09-18 | 成都康弘制药有限公司 | Application of pharmaceutical composition in preparation of drugs for preventing or treating fatty liver |
| CN103446494A (en) * | 2013-08-14 | 2013-12-18 | 南阳理工学院 | Chinese patent medicine for treating Type II diabetic nephropathy and preparation method thereof |
| CN104352645A (en) * | 2011-05-17 | 2015-02-18 | 成都康弘制药有限公司 | Pharmaceutical composition for preventing or treating diabetic complications |
| CN112190646A (en) * | 2020-11-19 | 2021-01-08 | 首都医科大学附属北京中医医院 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
-
2001
- 2001-05-21 CN CNB011084480A patent/CN1166382C/en not_active Expired - Lifetime
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049440B (en) * | 2006-04-03 | 2010-11-10 | 北京因科瑞斯生物制品研究所 | Preparation of Chinese traditional medicine in use for diabetes, and preparation method |
| CN101890098B (en) * | 2009-05-21 | 2012-03-14 | 中国中医科学院广安门医院 | Medicament for treating type II diabetic cardiopathy and preparation method thereof |
| CN101940716A (en) * | 2010-09-19 | 2011-01-12 | 薛红云 | Medicament for treating diabetic nephropathy |
| CN102100858A (en) * | 2011-01-29 | 2011-06-22 | 傅晓骏 | Chinese medicinal preparation for treating early diabetic nephropathy and preparation method thereof |
| CN102100858B (en) * | 2011-01-29 | 2012-02-22 | 傅晓骏 | Chinese medicinal preparation for treating early diabetic nephropathy and preparation method thereof |
| CN102784237A (en) * | 2011-05-17 | 2012-11-21 | 成都康弘制药有限公司 | Pharmaceutical composition for preventing or treating diabetic complications |
| CN102784238A (en) * | 2011-05-17 | 2012-11-21 | 成都康弘制药有限公司 | Application of pharmaceutical composition in preparation of drugs for preventing or treating neovascular diseases |
| CN104352645A (en) * | 2011-05-17 | 2015-02-18 | 成都康弘制药有限公司 | Pharmaceutical composition for preventing or treating diabetic complications |
| CN102784237B (en) * | 2011-05-17 | 2015-11-25 | 成都康弘制药有限公司 | Pharmaceutical composition for preventing or treating diabetic complications |
| CN103301243A (en) * | 2012-03-14 | 2013-09-18 | 成都康弘制药有限公司 | Application of pharmaceutical composition in preparation of drugs for preventing or treating fatty liver |
| CN103301243B (en) * | 2012-03-14 | 2015-06-17 | 成都康弘制药有限公司 | Application of pharmaceutical composition in preparation of drugs for preventing or treating fatty liver |
| CN102670842A (en) * | 2012-05-11 | 2012-09-19 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating diabetic nephropathy |
| CN103446494A (en) * | 2013-08-14 | 2013-12-18 | 南阳理工学院 | Chinese patent medicine for treating Type II diabetic nephropathy and preparation method thereof |
| CN103446494B (en) * | 2013-08-14 | 2015-02-04 | 南阳理工学院 | Chinese patent medicine for treating Type II diabetic nephropathy and preparation method thereof |
| CN112190646A (en) * | 2020-11-19 | 2021-01-08 | 首都医科大学附属北京中医医院 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1166382C (en) | 2004-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1047946C (en) | Preparation for treating senile diseases | |
| CN1245187C (en) | Medicine for treating eye disease caused by visceral disease | |
| CN1943761A (en) | A Medicine for treatment of ascites due to cirrhosis | |
| CN1347714A (en) | Chinese herb. medicine composition for treating diabetes and nephropathy and its preparing method | |
| CN101129588A (en) | Instant powder for conjunctivitis | |
| CN1726991A (en) | Medication of treating by dysenorrhea, irregular menses, weakness after childbirth for women, and preparation method | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN101983695A (en) | Traditional Chinese medicine composition for curing hemiplegia and preparation method thereof | |
| CN1279944C (en) | Medicine for treating cardiocerebral vascular system disease and blood supply deficiency, medicine preparing method and preparation | |
| CN101637548B (en) | Medicine for treating kidney stone and preparation method thereof | |
| CN1234407C (en) | Medicine for treating chronic prostatitis and its preparing method | |
| CN105770487A (en) | Traditional Chinese medicine composition for treating cerebral infarction and cerebral hemorrhage sequelae and preparation method thereof | |
| CN1965924A (en) | Medicament for lowering blood fat and dilating coronary artery | |
| CN1136939A (en) | Chinese drugs for curing hepatitis B | |
| CN1282475C (en) | Combination of medication for treating gallbladder disease and preparation method | |
| CN1253188C (en) | Medicine for treating hypertension and its preparing process | |
| CN103341021A (en) | Radiationproof Chinese herbal preparation for ultrasound department and preparation method of radiationproof Chinese herbal preparation | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN102755580B (en) | Method for preparing chewable tablets of drug for treating unstable angina pectoris | |
| CN1060677C (en) | Preparation for senile disease | |
| CN1194722C (en) | Shugan Zhitong soft extract for treating hepatitis | |
| CN105106817A (en) | Yao medicine compound broadleaf globethistle inflorescence tablet for treating diabetes and preparation method thereof | |
| CN1442167A (en) | Making method of capsule for treating hemorrhoid | |
| CN110237205A (en) | A kind of Chinese medicine composition of warming kidney and strengthening spleen and preparation method thereof | |
| CN1352979A (en) | Chinese medicine for replenishing vital energy and promoting blood circulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20040915 |